SLAIN2

Across TCGA pan-cancer cohorts, SLAIN2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLAIN2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLAIN2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLAIN2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where SLAIN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLAIN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	−0.109	<.001	10	view →
COAD	Male	III,IV	−0.308	<.001	8	view →
LUAD	All	All	+0.098	<.001	7	view →
PDAC	Female	All	+0.190	<.001	4	view →
HNSC	All	III,IV	+0.110	.034	3	view →
LSCC	All	All	+0.078	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLAIN2–CCRCC

Open the CCRCC breakdown →